rofecoxib has been researched along with Infections, Helicobacter in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight thousand seventy-six rheumatoid arthritis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofecoxib 50 mg daily or naproxen 500 mg twice daily for a median of 9 months." | 5.10 | Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. ( Bombardier, C; Brett, C; Davis, B; Hawkey, CJ; Laine, L; Reicin, A; Shapiro, D, 2002) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| " Dosing should be [figure: see text] cautious in old patients, however, because of the ability of NSAIDs and coxibs to cause fluid retention, heart failure, and hypertension." | 2.41 | Gastrointestinal safety of COX-2 specific inhibitors. ( Hawkey, CJ; Jones, JI, 2001) |
| "In indomethacin and rofecoxib-treated gerbils, the following results were obtained in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm2): 82." | 1.33 | Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. ( Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lien, GS; Lou, HY; Pan, S, 2005) |
| "Twenty-four gastric cancer (GC) patients entered this study and were examined twice, once before and then following a 14-day treatment with Vioxx at a dose of 25 mg twice daily." | 1.32 | Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. ( Bielanski, W; Hahn, EG; Hartwich, A; Kania, J; Konturek, PC; Konturek, SJ; Rehfeld, JF; Zuchowicz, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laine, L | 1 |
| Bombardier, C | 1 |
| Hawkey, CJ | 2 |
| Davis, B | 1 |
| Shapiro, D | 1 |
| Brett, C | 1 |
| Reicin, A | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Scheiman, JM | 1 |
| Greenson, JK | 1 |
| Lee, J | 1 |
| Cryer, B | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Bielanski, W | 1 |
| Kania, J | 1 |
| Zuchowicz, M | 1 |
| Hartwich, A | 1 |
| Rehfeld, JF | 1 |
| Hahn, EG | 1 |
| Kanatani, K | 1 |
| Ebata, M | 1 |
| Murakami, M | 1 |
| Okabe, S | 1 |
| Lamarque, D | 1 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Ebert, MP | 1 |
| Schäfer, C | 1 |
| Chen, J | 1 |
| Hoffmann, J | 1 |
| Gu, P | 1 |
| Kubisch, C | 1 |
| Carl-McGrath, S | 1 |
| Treiber, G | 1 |
| Malfertheiner, P | 1 |
| Röcken, C | 1 |
| McCarthy, DM | 1 |
| Jones, JI | 1 |
| Miyake, K | 1 |
| Sakamoto, C | 1 |
4 reviews available for rofecoxib and Infections, Helicobacter
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gas | 2002 |
Gastrointestinal safety of COX-2 specific inhibitors.
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygena | 2001 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2002 |
1 trial available for rofecoxib and Infections, Helicobacter
| Article | Year |
|---|---|
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Art | 2002 |
6 other studies available for rofecoxib and Infections, Helicobacter
| Article | Year |
|---|---|
Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.
Topics: Adult; Cell Division; Cyclooxygenase 2; Dinoprostone; Endoscopy, Gastrointestinal; Female; Follow-Up | 2003 |
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Topics: Aged; Apoptosis; Case-Control Studies; Caspase 3; Caspases; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2003 |
Effects of indomethacin and rofecoxib on gastric mucosal damage in normal and Helicobacter pylori-infected mongolian gerbils.
Topics: Administration, Oral; Animals; Dinoprostone; Drug Administration Schedule; Drug Synergism; Gastric A | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chronic Diseas | 2005 |
Protective role of heat shock protein 27 in gastric mucosal injury.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; | 2005 |